









Markets
/
Stocks
/
nasdaq-bioa
/

BIOAGE Labs Inc

BIOA

8.030USD

+0.200+2.55%

Market hours （ET）Quotes delayed by 15 min

287.88MMarket Cap

LossP/E TTM



BIOAGE Labs Inc

8.030

+0.200+2.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BIOAGE Labs Inc

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BIOAGE Labs Inc's Score

Industry at a Glance

Industry Ranking

96 / 407

Overall Ranking

205 / 4608

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Hold

Current Rating

9.667

Target Price

+29.06%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

BIOAGE Labs Inc Highlights

StrengthsRisks

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. It has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. It is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -3.83, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 24.62M shares, decreasing 12.22% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.65M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 6.66, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.66

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.19

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

BIOAGE Labs Inc's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 7.51, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.83, which is -121.79% below the recent high of 0.83 and -201.56% above the recent low of -11.54.

Score

Industry at a Glance

Previous score

7.51

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 96/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 6.50, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for BIOAGE Labs Inc is 9.00, with a high of 15.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

6.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Hold

Current Rating

9.667

Target Price

+23.46%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

522

Total

Median

Average

Company name

Ratings

Analysts

BIOAGE Labs Inc

BIOA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Exact Sciences Corp

EXAS

...

105

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 9.29, which is higher than the Biotechnology & Medical Research industry's average of 6.78. Sideways: Currently, the stock price is trading between the resistance level at 9.27 and the support level at 5.71, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.11

Change

0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.036

Neutral

RSI(14)

67.862

Neutral

STOCH(KDJ)(9,3,3)

61.212

Buy

ATR(14)

0.630

Low Volatility

CCI(14)

39.715

Neutral

Williams %R

41.622

Buy

TRIX(12,20)

1.431

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

7.510

Buy

MA10

7.542

Buy

MA20

6.959

Buy

MA50

5.926

Buy

MA100

5.208

Buy

MA200

4.696

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 68.68%, representing a quarter-over-quarter decrease of 3.00%. The largest institutional shareholder is The Vanguard, holding a total of 1.65M shares, representing 4.61% of shares outstanding, with 362.70% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Andreessen Horowitz

3.23M

Sofinnova Investments, Inc

2.30M

Cormorant Asset Management, LP

2.14M

-18.59%

Adar1 Capital Management LLC

1.94M

+99.48%

VK Services, LLC

1.80M

Longitude Capital Management Co., LLC

1.71M

+30.52%

The Vanguard Group, Inc.

Star Investors

1.56M

+123.25%

Tang Capital Management, LLC

1.60M

Fortney (Kristen Ph.D.)

1.21M

BlackRock Institutional Trust Company, N.A.

1.15M

+76.28%

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 3.56, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.